Exportar registro bibliográfico


Metrics:

Efficient and irreversible antibody–cysteine bioconjugation using carbonylacrylic reagents (2019)

  • Authors:
  • Autor USP: BURTOLOSO, ANTONIO CARLOS BENDER - IQSC
  • Unidade: IQSC
  • DOI: 10.1038/s41596-018-0083-9
  • Subjects: QUÍMICA ORGÂNICA; SÍNTESE ORGÂNICA
  • Agências de fomento:
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso à fonteDOI
    Informações sobre o DOI: 10.1038/s41596-018-0083-9 (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo é de acesso aberto
    • URL de acesso aberto
    • Cor do Acesso Aberto: green

    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      BERNARDIM, Barbara; MATOS, Maria J; FERHATI, Xhenti; et al. Efficient and irreversible antibody–cysteine bioconjugation using carbonylacrylic reagents. Nature Protocols, London, v. 14, n. Ja 2019, p. 86-99, 2019. Disponível em: < https://www.nature.com/articles/s41596-018-0083-9 > DOI: 10.1038/s41596-018-0083-9.
    • APA

      Bernardim, B., Matos, M. J., Ferhati, X., Compañón, I., Guerreiro, A., Akkapeddi, P., et al. (2019). Efficient and irreversible antibody–cysteine bioconjugation using carbonylacrylic reagents. Nature Protocols, 14( Ja 2019), 86-99. doi:10.1038/s41596-018-0083-9
    • NLM

      Bernardim B, Matos MJ, Ferhati X, Compañón I, Guerreiro A, Akkapeddi P, Burtoloso ACB, Jiménez-Osés G, Corzana F, Bernardes GJL. Efficient and irreversible antibody–cysteine bioconjugation using carbonylacrylic reagents [Internet]. Nature Protocols. 2019 ; 14( Ja 2019): 86-99.Available from: https://www.nature.com/articles/s41596-018-0083-9
    • Vancouver

      Bernardim B, Matos MJ, Ferhati X, Compañón I, Guerreiro A, Akkapeddi P, Burtoloso ACB, Jiménez-Osés G, Corzana F, Bernardes GJL. Efficient and irreversible antibody–cysteine bioconjugation using carbonylacrylic reagents [Internet]. Nature Protocols. 2019 ; 14( Ja 2019): 86-99.Available from: https://www.nature.com/articles/s41596-018-0083-9

    Referências citadas na obra
    Chudasama, V., Maruani, A. & Caddick, S. Recent advances in the construction of antibody–drug conjugates. Nat. Chem. 8, 114–119 (2016).
    Xue, L., Karpenko, I. A., Hiblot, J. & Johnsson, K. Imaging and manipulating proteins in live cells through covalent labeling. Nat. Chem. Biol. 11, 917–923 (2015).
    Rodrigues, T. & Bernardes, G. J. L. The missing link. Nat. Chem. 8, 1088–1090 (2016).
    Krall, N., da Cruz, F. P., Boutureira, O. & Bernardes, G. J. L. Site-selective protein-modification chemistry for basic biology and drug development. Nat. Chem. 8, 103–113 (2015).
    MacDonald, J. I., Munch, H. K., Moore, T. & Francis, M. B. One-step site-specific modification of native proteins with 2-pyridinecarboxyaldehydes. Nat. Chem. Biol. 11, 326–331 (2015).
    Vinogradova, E. V., Zhang, C., Spokoyny, A. M., Pentelute, B. L. & Buchwald, S. L. Organometallic palladium reagents for cysteine bioconjugation. Nature 526, 687–691 (2015).
    Boutureira, O. & Bernardes, G. J. L. Advances in chemical protein modification. Chem. Rev. 115, 2174–2195 (2015).
    Matos, M. J. et al. Chemo- and regioselective lysine modification on native proteins. J. Am. Chem. Soc. 140, 4004–4017 (2018).
    Beck, A., Goetsch, L., Dumontet, C. & Corvaïa, N. Strategies and challenges for the next generation of antibody–drug conjugates. Nat. Rev. Drug Discov. 16, 315–337 (2017).
    Sievers, E. L. & Senter, P. D. Antibody-drug conjugates in cancer therapy. Ann. Rev. Med. 64, 15–29 (2013).
    Bernardim, B. et al. Stoichiometric and irreversible cysteine-selective protein modification using carbonylacrylic reagents. Nat. Commun. 7, 13128 (2016).
    Junutula, J. R. et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 26, 925–932 (2008).
    Stenton, B. J., Oliveira, B. L., Matos, M. J., Sinatra, L. & Bernardes, G. J. L. A thioether-directed palladium-cleavable linker for targeted bioorthogonal drug decaging. Chem. Sci. 9, 4185–4189 (2018).
    Rosen, C. B. & Francis, M. B. Targeting the N terminus for site-selective protein modification. Nat. Chem. Biol. 13, 697–705 (2017).
    Chalker, J. M., Bernardes, G. J. L., Lin, Y. A. & Davis, B. G. Chemical modification of proteins at cysteine: opportunities in chemistry and biology. Chem. Asian J. 4, 630–640 (2009).
    Pimenta Góis, P. M., Ravasco, J., Faustino, H. & Trindade, A. Bioconjugation with maleimides: a useful tool for chemical biology. Chem. Eur. J. doi:10.1002/chem.201803174 (2018).
    Kalia, D., Malekar Pushpa, V. & Parthasarathy, M. Exocyclic olefinic maleimides: synthesis and application for stable and thiol‐selective bioconjugation. Angew. Chem. Int. Ed. Engl. 55, 1432–1435 (2015).
    Lyon, R. P. et al. Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates. Nat. Biotechnol. 32, 1059–1062 (2014).
    Vaneycken, I. et al. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J. 25, 2433–2446 (2011).
    Lyon, R. P. et al. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat. Biotechnol. 33, 733–735 (2015).
    Freedy, A. M. et al. Chemoselective installation of amine bonds on proteins through aza-Michael ligation. J. Am. Chem. Soc. 139, 18365–18375 (2017).
    Levengood, M. R. et al. Orthogonal cysteine protection enables homogeneous multi-drug antibody–drug conjugates. Angew. Chem. Int. Ed. Engl. 56, 733–737 (2017).
    Senter, P. D. & Sievers, E. L. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat. Biotechnol. 30, 631–637 (2012).
    Carl, P. L., Chakravarty, P. K. & Katzenellenbogen, J. A. A novel connector linkage applicable in prodrug design. J. Med. Chem. 24, 479–480 (1981).
    Cui, J. J. et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal–epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J. Med. Chem. 54, 6342–6363 (2011).
    Brack, S. S., Silacci, M., Birchler, M. & Neri, D. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-c. Clin. Cancer Res. 12, 3200–3208 (2006).
    Heuveling, D. A. et al. Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients. J. Nucl. Med. 54, 397–401 (2013).
    Gébleux, R., Stringhini, M., Casanova, R., Soltermann, A. & Neri, D. Non‐internalizing antibody–drug conjugates display potent anti‐cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix. Int. J. Cancer 140, 1670–1679 (2016).

Digital Library of Intellectual Production of Universidade de São Paulo     2012 - 2021